CROI 2015: Varenicline Helps People with HIV Stop Smoking, but Success Rate Remains Low

The smoking cessation drug varenicline (Chantix) helped more people with HIV to stop smoking than counseling alone, but less than 20% were able to remain abstinent for a year, according to the results of a French study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.The smoking cessation rates in this study were comparable to those previously seen for HIV-negative people using varenicline or other methods -- across the board only a minority manage to quit long-term.


CROI 2015: Smoking and Its Detrimental Outcomes for People with HIV

Smoking and its consequences was a major topic at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Researchers presented findings on smoking as a risk factor for cancer, CT scans to detect early lung cancer, and varenicline for smoking cessation.

Smoking Outweighs HIV-Related Risk Factors for Non-AIDS Cancers

Screening Finds High Prevalence of Early-Stage Lung Cancer in Smokers with HIV

Varenicline Helps People with HIV Stop Smoking



CROI 2015: Study Finds High Rates of Cancer Among Elderly People with HIV

Elderly people living with HIV (over the age of 65) are at greatly increased risk of HIV-associated cancers, though many of the most commonly diagnosed cancers may be related more to aging than to HIV itself, according to a study reported last week at the at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).


CROI 2015: HIV Attachment Inhibitor BMS-663068 Shown Safe and Effective in Phase 2b Study

Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Related research showed that BMS-663068 can safely be taken with antiretrovirals commonly used by treatment-experienced patients. A Phase 3 trial is now underway.


CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP

Levels of the HIV entry inhibitor maraviroc (Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection against HIV in a laboratory study, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Multiple doses, however, could still potentially be effective for pre-exposure prophylaxis, or PrEP.


CROI 2015: Treatment Cascades and Viral Load Surveys Inform ART as Prevention in Africa

Reaching ambitious HIV prevention targets in South Africa will require intensified efforts to engage and retain men and young people in care, in order to increase the proportion of people on HIV treatment with suppressed viral load, according to a national study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) last week in Seattle. Another study, conducted in 3 countries in sub-Saharan Africa, showed that to maximize the preventive effect of antiretroviral therapy (ART), efforts to expand treatment coverage need to focus on those with the highest viral load off treatment -- mainly people who are already eligible for treatment under current guidelines.


CROI 2015: Disappointing Result for Tenofovir Gel Microbicide

Among some highly promising results from HIV prevention studies presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle, there was one disappointment. FACTS 001, a study testing the efficacy against HIV of a vaginal microbicide gel containing tenofovir, produced a null result: there was no difference in the HIV infection rate for young women given the active gel and the rate for those given a placebo gel.